Burden & Treatment Considerations For Agitation Associated With Alzheimer’s Dementia
Agitation associated with Alzheimer’s Dementia (AAD) may lead to worsening outcomes in an already devastating disease. A patient centered focus is recommended for a comprehensive treatment plan. In this webinar, the speakers will review the burden of AAD, then discuss current treatment recommendations and unmet needs.
Objectives:
- Review the patient, caregiver, and economic burden related to agitation associated with Alzheimer’s Disease (AAD) caregiver
- List the currently available treatment recommendations and guidelines for AAD
- Identify gaps with current treatment options, both pharmacologic and nonpharmacologic
William Clay Jackson, MD, DipTh
Assistant Professor of Clinical Psychiatry & Family Medicine; University of TN College of Medicine
Bryan Archuleta, PharmD
Senior Long-Term Care Medical Science Liaison
W. Clay Jackson is a paid consultant of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC)
Bryan Archuleta is an employee of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC)
Disclaimer: PsychU is supported by Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC), Otsuka America Pharmaceutical, Inc. (OAPI), and Lundbeck, LLC – committed supporters of the mental health treatment community. The opinions expressed by PsychU’s contributors are their own and are not endorsed or recommended by PsychU or its sponsors. The information provided through PsychU is intended for the educational benefit of mental health care professionals and others who support mental health care. It is not intended as, nor is it a substitute for, medical care, advice, or professional diagnosis. Health care professionals should use their independent medical judgement when reviewing PsychU’s educational resources. Users seeking medical advice should consult with a health care professional. No CME or CEU credits are available through any of the resources provided by PsychU. Some of the contributors may be paid consultants for OPDC, OAPI, and / or Lundbeck, LLC.
-
Psychometric Validation of the AASC®: Supporting Early Detection & Improving Caregiver-HCP communication in Agitation Associated With Dementia Due to Alzheimer’s Disease (AAD)
In this webinar, Dr. Carolyn Clevenger will provide both background on AASC® tool development and details on AASC® quantitative validation study design and results.